.jpg "RedHill Biopharma (NASDAQ: RDHL)")
RedHill Biopharma (RDHL) received a Buy rating and a $9 price target from WBB Securities analyst Stephen Brozak today. The company’s shares closed on Friday at $5.36, close to its 52-week low of $4.40.
According to TipRanks.com, Brozak is a 4-star analyst with an average return of 9.5% and a 42.6% success rate. Brozak covers the Healthcare sector, focusing on stocks such as Marker Therapeutics Inc, Kadmon Holdings, and ADMA Biologics.
RedHill Biopharma has an analyst consensus of Strong Buy, with a price target consensus of $26.33.
See today’s analyst top recommended stocks >>
Based on RedHill Biopharma’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $9.83 million. In comparison, last year the company had a GAAP net loss of $10.71 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
RedHill Biopharma Ltd. is a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary drugs for the treatment of gastrointestinal diseases. RedHill’s pipeline includes several drug candidates in advanced clinical development stages, including three Phase III-stage programs.
